OTCMKTS:ARTH - Arch Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.3820 -0.02 (-4.98 %) (As of 02/19/2019 03:58 PM ET)Previous Close$0.40Today's Range$0.38 - $0.4152-Week Range$0.26 - $0.69Volume287,773 shsAverage Volume233,228 shsMarket Capitalization$62.63 millionP/E RatioN/ADividend YieldN/ABeta-0.2 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts. Receive ARTH News and Ratings via Email Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CUSIPN/A Webwww.archtherapeutics.com Phone617-431-2313Debt Debt-to-Equity RatioN/A Current Ratio13.37 Quick Ratio13.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,810,000.00 Net MarginsN/A Return on Equity-622.59% Return on Assets-168.51%Miscellaneous Employees9 Outstanding Shares163,947,000Market Cap$62.63 million OptionableNot Optionable Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions What is Arch Therapeutics' stock symbol? Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH." How were Arch Therapeutics' earnings last quarter? Arch Therapeutics Inc (OTCMKTS:ARTH) announced its quarterly earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). View Arch Therapeutics' Earnings History. When is Arch Therapeutics' next earnings date? Arch Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Arch Therapeutics. What price target have analysts set for ARTH? 4 analysts have issued 12-month price targets for Arch Therapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Arch Therapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 685.3% from the stock's current price. View Analyst Price Targets for Arch Therapeutics. What is the consensus analysts' recommendation for Arch Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arch Therapeutics. Has Arch Therapeutics been receiving favorable news coverage? Media coverage about ARTH stock has trended somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arch Therapeutics earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. Who are some of Arch Therapeutics' key competitors? Some companies that are related to Arch Therapeutics include Liquidia Technologies (LQDA), T2 Biosystems (TTOO), RenovaCare (RCAR), Sensus Healthcare (SRTS), STRATA Skin Sciences (SSKN), iCAD (ICAD), RA Medical Systems (RMED), Apollo Endosurgery (APEN), Invo Bioscience (IVOB), CAS Medical Systems (CASM), Motus GI (MOTS), Pro-Dex (PDEX), Titan Medical (TMDI), Alphatec (ATEC) and Spectral Medical (EDTXF). Who are Arch Therapeutics' key executives? Arch Therapeutics' management team includes the folowing people: Dr. Terrence W. Norchi, Chairman, Pres, CEO, Sec. & Director (Age 54)Mr. Richard E. Davis, CFO & Treasurer (Age 61)Dr. Avtar S. Dhillon, Bus. Advisor (Age 57)Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific AdvisorDr. Steven A. Kates Ph.D., VP of Technology How do I buy shares of Arch Therapeutics? Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arch Therapeutics' stock price today? One share of ARTH stock can currently be purchased for approximately $0.3820. How big of a company is Arch Therapeutics? Arch Therapeutics has a market capitalization of $62.63 million. Arch Therapeutics employs 9 workers across the globe. What is Arch Therapeutics' official website? The official website for Arch Therapeutics is http://www.archtherapeutics.com. How can I contact Arch Therapeutics? Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected] MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 141 (Vote Outperform)Underperform Votes: 149 (Vote Underperform)Total Votes: 290MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: What is Cost of Goods Sold (COGS)?